Get Connected:

The International Liver Congress 2014 / 49th Annual Meeting of the European Association for the Study of the Liver will feature an impressive array of scientific and educational content covering viral hepatitis, liver transplantation, and other topics in liver disease.
International Liver Congress 2014

International Liver Congress 2014 | EASL 2014

Conference Coverages

The Power of 'Big Data' and the Impact of Screening on Hepatitis C Survival Rates
The Power of 'Big Data' and the Impact of Screening on Hepatitis C Survival Rates
A large multinational observational study of patients with hepatitis C reveals etiology does not play a major role in HCV survival rates and that early detection and access to treatment have a greater impact.
Combination Therapy with ABT-450/Ritonavir/Ombitasvir Is Highly Effective in Liver Transplant Patients with Hepatitis C
Preliminary results from the M12-999 study show that treatment with ABT-450/ritonavir/ombitasvir plus dasabuvir and ribavirin is well tolerated and associated with high rates of sustained virologic response in adult liver transplant recipients with recurrent HCV genotype 1 infection.
Is There Any Advantage to Treating Patients with Hepatitis C for Longer than 12 Weeks with Combination Sofosbuvir/Ledipasvir?
Results from the phase III ION-2 study show a 24-week regimen of sofosbuvir/ledipasvir does not produce significantly better cure rates than a 12-week regimen in treatment-experienced patients.
Evaluating Combination Therapy vs. Monotherapy in Hepatitis B
Results from the NEED study show combination treatment with peginterferon alpha-2a and either adefovir or entecavir does not increase HBeAg seroconversion rate compared to monotherapy alone in patients with hepatitis B.
Interferon-free Triple Therapy Is Safe and Effective for Hepatitis C
Results from the SAPPHIRE-I trial show that Abbvie’s 3D therapy produced 96% sustained viral response rates at 12 weeks in treatment-naive patient with genotype 1 hepatitis C.
New Treatment Options for Patients with Hepatitis C Genotype 4
Data from the PEARL-I trial of patients with hepatitis C genotype 4 show high rates of sustained virologic response at 12 weeks associated with combination treatment with ABT-450 (a protease inhibitor boosted by ritonavir) and ombitasvir.
Encouraging Results from the ION-3 Study of Treatment-naïve Patients with Hepatitis C without Cirrhosis
An 8-week course of treatment with a fixed dose combination of ledipasvir plus sofosbuvir produced sustained virologic response in more than 90 percent of treatment-naïve patients with genotype 1 hepatitis C.

Most Popular

$vacMongoViewPlus$ $vAR$